138 related articles for article (PubMed ID: 27872451)
1. Update on the mechanisms of action of anti‑TNF-α antibodies and their clinical implications in inflammatory bowel disease.
Eder P; Linke K; Witowski J
Pol Arch Med Wewn; 2016 Sep; 126(10):772-780. PubMed ID: 27872451
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases.
Olesen CM; Coskun M; Peyrin-Biroulet L; Nielsen OH
Pharmacol Ther; 2016 Mar; 159():110-9. PubMed ID: 26808166
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
Danese S
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works?
Oikonomopoulos A; van Deen WK; Hommes DW
Curr Drug Targets; 2013 Nov; 14(12):1421-32. PubMed ID: 23627866
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
Billmeier U; Dieterich W; Neurath MF; Atreya R
World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
[TBL] [Abstract][Full Text] [Related]
7. Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases.
Atreya R; Neurath MF
Dig Dis; 2016; 34(5):552-7. PubMed ID: 27333283
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.
Chaparro M; Guerra I; Muñoz-Linares P; Gisbert JP
Aliment Pharmacol Ther; 2012 May; 35(9):971-86. PubMed ID: 22443153
[TBL] [Abstract][Full Text] [Related]
9. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
10. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
[TBL] [Abstract][Full Text] [Related]
11. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR
J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
[TBL] [Abstract][Full Text] [Related]
12. Functional relevance of soluble TNF-alpha, transmembrane TNF-alpha and TNF-signal transduction in gastrointestinal diseases with special reference to inflammatory bowel diseases.
Holtmann MH; Schütz M; Galle PR; Neurath MF
Z Gastroenterol; 2002 Aug; 40(8):587-600. PubMed ID: 12297983
[TBL] [Abstract][Full Text] [Related]
13. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
Allez M; Karmiris K; Louis E; Van Assche G; Ben-Horin S; Klein A; Van der Woude J; Baert F; Eliakim R; Katsanos K; Brynskov J; Steinwurz F; Danese S; Vermeire S; Teillaud JL; Lémann M; Chowers Y
J Crohns Colitis; 2010 Oct; 4(4):355-66. PubMed ID: 21122530
[TBL] [Abstract][Full Text] [Related]
14. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.
Veerappan SG; O'Morain CA; Daly JS; Ryan BM
Aliment Pharmacol Ther; 2011 Jun; 33(12):1261-72. PubMed ID: 21521250
[TBL] [Abstract][Full Text] [Related]
15. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases].
Allez M
Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):467-77. PubMed ID: 18448294
[No Abstract] [Full Text] [Related]
16. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
Peng JC; Shen J; Ran ZH
J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
[TBL] [Abstract][Full Text] [Related]
17. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.
Chowers Y; Sturm A; Sans M; Papadakis K; Gazouli M; Harbord M; Jahnel J; Mantzaris GJ; Meier J; Mottet C; Peyrin-Biroulet L; Allez M
J Crohns Colitis; 2010 Oct; 4(4):367-76. PubMed ID: 21122531
[TBL] [Abstract][Full Text] [Related]
18. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
[TBL] [Abstract][Full Text] [Related]
19. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.
Cha JM; Park DI; Park SH; Shin JE; Kim WS; Yang SK
J Korean Med Sci; 2017 Jan; 32(1):85-94. PubMed ID: 27914136
[TBL] [Abstract][Full Text] [Related]
20. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.
Eder P; Zielińska A; Karczewski J; Dobrowolska A; Słomski R; Souto EB
J Nanobiotechnology; 2021 Oct; 19(1):346. PubMed ID: 34715852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
